Immunotherapy is a rapidly expanding field of oncology aimed at targeting, not the tumor
itself, but the immune system combating the cancerous lesion. Of the many approaches …

Neutrophils have historically been characterized as first responder cells vital to host survival
because of their ability to contain and eliminate bacterial and fungal pathogens. However …

Purpose: Urelumab is an agonist antibody to CD137 with potential application as an
immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and …

Costimulation of T cell responses with monoclonal antibody agonists (mAb-AG) targeting 4-
1BB showed robust anti-tumor activity in preclinical models, but their clinical development …

Originally discovered as a T cell-activating molecule, 4-1BB (CD137) is now also recognized
as an activator of non-T cells, thus imparting a new dimension to its potential in vivo effects …

Previous studies have suggested that neutrophils are required for resistance during infection
with multiple pathogenic microorganisms. However, the depleting antibody used in those …

Immunostimulatory cues play an important role in priming antitumor immunity and promoting
the efficacy of subunit cancer vaccines. However, the clinical use of many …

As an immune adjuvant, proinflammatory allogeneic dendritic cells (AlloDCs) have
demonstrated promising immune-priming effects in several preclinical and clinical studies …

Severe sepsis and septic shock caused mainly by bacterial infections are life-threatening
conditions that urge the development of novel therapies. However, host responses to and …

Activation of innate immunity together with cholangiocyte damage occurs in biliary atresia
(BA). However, detailed information on the inflammatory cells involved is lacking. This study …